Navigation Links
Cephalon Reports Strong First Quarter Earnings
Date:5/1/2008

sion), GABITRIL(R) (tiagabine hydrochloride), and ACTIQ. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products, including the growth and acceptance of AMRIX in the market and the relative success of the recent launch of Treanda; sales, adjusted net income and basic adjusted income per common share guidance for the second quarter and full-year 2008 and SG&A and R&D guidance for the full-year 2008; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such fac
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Cephalon Appoints Gerald J. Pappert as General Counsel
2. inVentiv Selling Solutions Selected to Provide Sales Team for Cephalon Inc.
3. Cephalon to Present at the 26th Annual JP Morgan Healthcare Conference
4. Cephalon Appoints Valli F. Baldassano as Executive Vice President and Chief Compliance Officer
5. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
6. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
7. Haemonetics Reports Strong Results for Fourth Quarter and Fiscal Year End 2008 and Issues Guidance for Continued Strong Growth in Fiscal 2009
8. Nu Skin Enterprises Reports First-Quarter 2008 Results
9. Cardinal Health Reports Third Quarter Results
10. BioMed Realty Trust Reports First Quarter 2008 Financial Results
11. Cardiac Science Reports Strong Q1 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 ... weights, breast milk is more likely than a blood transfusion ... (CMV), a new study finds. The researchers evaluated more ... whom weighed 3.3 pounds or less and many who were ... see whether breast milk or transfusions carried the bigger risk. ...
(Date:9/23/2014)... San Francisco, CA (PRWEB) September 23, 2014 ... search for original 1967 The Doors Eagle Auditorium Seattle concert ... of their album “Break On Through” that year. The Seattle ... According to Hawley, “The Doors would return to Eagles Auditorium ... Doors July poster is not known and comes in three ...
(Date:9/23/2014)... 23, 2014 (HealthDay News) -- The number of ... drugs is growing, so doctors need to be ... Drug Administration warned Tuesday. In a statement, ... that it has launched a program to educate ... about proper drug purchasing procedures. The program aims ...
(Date:9/23/2014)... Vancouver Electrician Contractors, Pro Ace, has ... electrical services in Vancouver, BC. The company will provide ... a small maintenance project or a large-scale new installation ... meet the needs of the individual commercial client. Pro ... of an affordable price. As a result, businesses of ...
(Date:9/23/2014)... September 23, 2014 The University ... research university located In the Piedmont Triad, announced ... as co-director of the Center for Translational Biomedical ... comes to UNCG after nearly a decade at ... Laboratory, Biological Sciences Division. , “Our goal ...
Breaking Medicine News(10 mins):Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2
... improve the effectiveness of the only tuberculosis vaccine approved ... in a pre-clinical test, report scientists at The University ... Nature Medicine ,s Advance Online Publication March 1. Their ... funded by the National Institutes of Health (NIH). ...
... Medical Event Available from the Convenience of a Computer, www.CardioCareLive.com ... from 9:30 AM to 8:00 PM Eastern.,Patch Adams, MD, the real ... speak. To register now for free, visit cardioCareLive.com. , ... ...
... American Public Health Association,s (APHA) new Fluoridation Position ... support nor evaluate fluoridation,s safety and/or effectiveness as ... Fluoridation, Inc. APHA asserts, "All of these reviews ... safe and effective." Here,s the truth about APHA,s ...
... drug-eluting stentNATICK, Mass., March 3 Boston Scientific ... the launch of its TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary ... approved on January 28 by the Ministry of ... yesterday by the National Health Insurance System.TAXUS Liberte ...
... patients, the soles of their feet and the palms of ... because of some types of chemotherapy. Patients, family members also ... , Both share a need for quick answers or ... diagnosis, treatments, or unexpected symptoms. , A new section ...
... to Defend His TitleNORTHRIDGE, Calif., March 3 There ... names, two decks of shuffled playing cards, or a ... minutes. Chester Santos, the 2008 USA National Memory Champion, ... when he defends his title at the USA National ...
Cached Medicine News:Health News:TB breakthrough could lead to stronger vaccine 2Health News:TB breakthrough could lead to stronger vaccine 3Health News:CardioCareLive, First-Ever Online Cardiometabolic Conference, Debuts Today 2Health News:APHA Misleads Americans About Fluoridation 2Health News:Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System 2Health News:Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System 3Health News:Walther Cancer Foundation grant funds new IU Simon Cancer Center Web site section 2Health News:The Making of a Memory Champion 2Health News:The Making of a Memory Champion 3
(Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
(Date:9/23/2014)...  SiteOne Therapeutics Inc. today announced the completion of ... Capital Management and Biobrit LLC, with additional investors Mission ... million financing positions SiteOne to advance its oral Na ... develop its technology platform for long-acting local analgesics, pain ... with the financing, Lowell Sears (Sears Capital ...
(Date:9/23/2014)... Sept. 23, 2014  KemPharm, Inc., a clinical-stage ... development of proprietary new molecular entity (NME) prodrugs, ... Letter (NOL) from Health Canada to begin clinical ... its lead product candidate KP201 (benzhydrocodone hydrochloride and ... for acute moderate to moderately severe pain. The ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 2KemPharm Receives Health Canada Approval to Begin KP201 Clinical Trials in Canada 3
... PXS) today announced significant results of pooled data from ... of Bronchitol (inhaled mannitol) in people with cystic fibrosis. ... the first time at the North American Cystic Fibrosis ... results from the second trial (CF302) have been released ...
... Oct. 22 INVO Bioscience, Inc. (OTC Bulltin Board: ... for patients diagnosed with infertility, today announced that Dr. ... (CECOFLES LTDA) will present the results of the first ... INVO Bioscience,s INVOcell technology at the 66th Annual Meeting ...
Cached Medicine Technology:Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 2Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 3Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 4Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results 5INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine 2INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine 3
Transcranial vascular DWL doppler....
... is an automated system capable of handling ... definition of many of the tests allows ... your patients' and staffs' needs. Any tests ... automated tests can easily be handled using ...
The CD Horizon M10 Spinal System provide spine surgeons comprehensive solutions for the treatment of spinal deformities, trauma reconstruction, and degenerative conditions....
... Neurocare - continues the revolutionary ... Exceptional convenience and speed. Superior Doppler ... delivers features you won't find anywhere ... cuff attachment and testing. Up to ...
Medicine Products: